Asia Pacific Cerebrospinal Fluid Management Market Forecast to 2030 - Regional Analysis - by Product (CSF Shunts and CSF Drainage Systems) and End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others)

Description

List of Tables

The Asia Pacific cerebrospinal fluid management market was valued at US$ 389.53 million in 2022 and is expected to reach US$ 613.54 million by 2030; it is estimated to grow at a CAGR of 5.8% from 2022 to 2030.

Increasing Focus on CSF Management in Neurological Disease Treatments Fuels the Asia Pacific Cerebrospinal Fluid Management Market

CSF parameters are extensively evaluated as biomarkers of neurological disorders in adult patients. Circulating microRNAs in CSF are a promising class of biomarkers for the diagnosis of various neurological diseases. Neurological disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), epilepsy, and seizures often lead to altered CSF parameters. According to an article published in Nature, 76 CSF proteins were found to be structurally altered in patients that were diagnosed with PD when compared to normal individuals. The study also suggests that these CSF proteins can be used as biomarkers for the diagnosis or treatment of the disease. PD is a neurodegenerative disease associated with loss of cognitive impairment and motor function. According to the World Health Organization (WHO) report published in 2022, the prevalence of PD has doubled in the last 25 years, affecting ~1% of the global population aged more than 60 years. Similarly, a few of the CSF parameters such as protein and lactate levels are altered in patients suffering from seizure or status epilepticus. Therefore, various R&D activities are going on for using CSF parameters in the treatment of seizures or epilepsy. Further, despite the availability of various CSF assays for the detection of Alzheimer's disease using CSF in the market, there are unmet needs for biomarkers for detection and treatment purposes. As the detection of cases of Alzheimer's disease and PD increases, there is increase in demand for CSF management devices as the cases of CSF leaks may increases. Therefore, a rise in the prevalence of neurological disorders is fueling the research and development activities for the use of CSF management products in the treatment of these disorders.

Asia Pacific Cerebrospinal Fluid Management Market Overview

The Asia Pacific cerebrospinal fluid management is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Asia Pacific is the fastest-growing market for cerebrospinal fluid management in global scenario. The cerebrospinal fluid management market growth in this region is attributed to growing geriatric population, demand for advanced medical devices, and increasing healthcare infrastructures offering efficient treatments.

Asia Pacific Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)

Asia Pacific Cerebrospinal Fluid Management Market Segmentation

The Asia Pacific cerebrospinal fluid management market is segmented into product, end user and country.

Based on product, the Asia Pacific cerebrospinal fluid management market is bifurcated into CSF shunts and CSF drainage systems. The CSF shunts segment held a larger market share in 2022.

Based on end user, the Asia Pacific cerebrospinal fluid management market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest market share in 2022.

Based on country, the Asia Pacific cerebrospinal fluid management market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific cerebrospinal fluid management market share in 2022.

B. Braun SE, Integra LifeSciences Holdings Corp, Medtronic Plc, Natus Medical Inc, and Spiegelberg GmbH & Co KG are some of the leading companies operating in the Asia Pacific cerebrospinal fluid management market.

Product Code: TIPRE00028018

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Cerebrospinal Fluid Management Market Landscape

4.1 Overview
4.2 Asia Pacific PEST Analysis

5. Asia Pacific Cerebrospinal Fluid Management Market - Key Industry Dynamics

5.1 Market Drivers
- 5.1.1 Increasing Cases of Cerebrospinal Fluid Leaks
- 5.1.2 Government Initiatives for Addressing Growing Challenges Associated with CSF
5.2 Market Restraints
- 5.2.1 Risk of Failure and Malfunctioning
5.3 Market Opportunities
- 5.3.1 Increasing Focus on CSF Management in Neurological Disease Treatments
5.4 Future Trends
- 5.4.1 Development of Smart Cerebrospinal Fluid Shunts
5.5 Impact Analysis:

6. Cerebrospinal Fluid Management Market - Asia Pacific Market Analysis

6.1 Asia Pacific Cerebrospinal Fluid Management Market Revenue (US$ Mn), 2022 - 2030

7. Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 - by Product

7.1 Overview
7.2 Asia Pacific Cerebrospinal Fluid Management Market Revenue Share, by Product 2022 & 2030 (%)
7.3 CSF Shunts
- 7.3.1 Overview
- 7.3.2 CSF Shunts: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
- 7.3.3 Ventriculoperitoneal Shunts
  - 7.3.3.1 Overview
  - 7.3.3.2 Ventriculoperitoneal Shunts: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
- 7.3.4 Ventriculoatrial Shunts
  - 7.3.4.1 Overview
  - 7.3.4.2 Ventriculoatrial Shunts: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
- 7.3.5 Ventriculopleural Shunts
  - 7.3.5.1 Overview
  - 7.3.5.2 Ventriculopleural Shunts: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
- 7.3.6 Lumboperitoneal Shunts
  - 7.3.6.1 Overview
  - 7.3.6.2 Lumboperitoneal Shunts: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
7.4 CSF Drainage Systems
- 7.4.1 Overview
- 7.4.2 CSF Drainage Systems: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
- 7.4.3 External Ventricular Drainage (EVD) Systems
  - 7.4.3.1 Overview
  - 7.4.3.2 External Ventricular Drainage (EVD) Systems: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
- 7.4.4 Lumbar Drainage (LD) Systems
  - 7.4.4.1 Overview
  - 7.4.4.2 Lumbar Drainage (LD) Systems: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 - by End User

8.1 Overview
8.2 Asia Pacific Cerebrospinal Fluid Management Market Revenue Share, by End User 2022 & 2030 (%)
8.3 Hospitals
- 8.3.1 Overview
- 8.3.2 Hospitals: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Clinics
- 8.4.1 Overview
- 8.4.2 Clinics: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Ambulatory Surgical Centers
- 8.5.1 Overview
- 8.5.2 Ambulatory Surgical Centers: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Cerebrospinal Fluid Management Market - Country Analysis

9.1 Overview

10. Asia Pacific Cerebrospinal Fluid Management Market -Industry Landscape

10.1 Overview
10.2 Growth Strategies in The Asia Pacific Cerebrospinal Fluid Management Market, 2020-2023
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Medtronic Plc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Integra LifeSciences Holdings Corp
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 B. Braun SE
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Natus Medical Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Spiegelberg GmbH & Co KG
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms